29,920 results match your criteria Hyperparathyroidism


How radical is total parathyroidectomy in patients with renal hyperparathyroidism?

Langenbecks Arch Surg 2018 Dec 5. Epub 2018 Dec 5.

Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University of Vienna, Waehringer Gürtel 18-20, A-1090, Vienna, Austria.

Purpose: Total parathyroidectomy (tPTX) in patients with renal hyperparathyroidism (RHPT) aims at the complete removal of all hyperfunctioning parathyroid tissue. Whenever parathyroidectomy is termed "total," undetectable postoperative parathyroid hormone (PTH) levels within the first postoperative week are expected. The aim of this study was to evaluate if tPTX is technically possible using a radical surgical procedure. Read More

View Article
December 2018

Vertebral fractures cascade: potential causes and risk factors.

Osteoporos Int 2018 Dec 5. Epub 2018 Dec 5.

Rheumatology Department, INSERM 1153, CHU Paris Cochin, Paris Descartes University, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France.

We performed a study to identify potential causes and risk factors of vertebral fracture cascade. Vertebral fracture cascade is a severe clinical event in patients with bone fragility. Only half of patients have an identified cause of secondary osteoporosis. Read More

View Article
December 2018

Randomized trial of intravenous iron-induced hypophosphatemia.

JCI Insight 2018 Dec 6;3(23). Epub 2018 Dec 6.

AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA.

Background: Hypophosphatemia can complicate intravenous iron therapy, but no head-to-head trials compared the effects of newer intravenous iron formulations on risks and mediators of hypophosphatemia.

Methods: In a randomized, double-blinded, controlled trial of adults with iron deficiency anemia from February 2016 to January 2017, we compared rates of hypophosphatemia in response to a single FDA-approved course of ferric carboxymaltose (n = 1,000) or ferumoxytol (n = 997). To investigate pathophysiological mediators of intravenous iron-induced hypophosphatemia, we nested within the parent trial a physiological substudy (ferric carboxymaltose, n = 98; ferumoxytol, n = 87) in which we measured fibroblast growth factor 23 (FGF23), calcitriol, and parathyroid hormone (PTH) at baseline and 1, 2, and 5 weeks later. Read More

View Article
December 2018
2 Reads

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.

Pediatr Nephrol 2018 Nov 30. Epub 2018 Nov 30.

Heidelberg University Hospital, Heidelberg, Germany.

Background: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in children with secondary hyperparathyroidism (SHPT) receiving dialysis.

Methods: This study had double-blind and open-label phases. Eligible patients aged 6-< 18 years were randomized to cinacalcet (starting dose ≤ 0. Read More

View Article
November 2018

Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: Presentations, causes and treatment strategies.

Authors:
Sherifa A Hamed

Expert Rev Clin Pharmacol 2018 Dec 2. Epub 2018 Dec 2.

a Department of Neurology and Psychiatry , Assiut University Hospital , Assiut , Egypt.

Introduction: Uremic syndrome of chronic kidney disease (CKD) is a term used to describe clinical, metabolic and hormonal abnormalities associated with progressive kidney failure. It is a rapidly growing public health problem worldwide. Nervous system complications occur in every patient with uremic syndrome of CKD. Read More

View Article
December 2018

Evaluation of Oxalate Osteopathy Secondary to Hyperoxaluria With 18F-FDG PET/CT and 99mTc-HMDP Bone Scan.

Clin Nucl Med 2018 Dec 3. Epub 2018 Dec 3.

We report a case of a 69-year-old woman with primary hyperoxaluria type I, who developed a severe hypercalcemia despite controlled secondary hyperparathyroidism. Bone scintigraphy showed diffuse increased uptake in axial and peripheral skeleton. F-FDG PET/CT showed countless striking hypermetabolic foci, interesting 2 types of lesions (joint calcifications and periosteal resorptions). Read More

View Article
December 2018

The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD.

Nutrients 2018 Dec 3;10(12). Epub 2018 Dec 3.

Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

In chronic kidney disease (CKD), hyperphosphatemia induces fibroblast growth factor-23 (FGF-23) expression that disturbs renal 1,25-dihydroxy vitamin D (1,25D) synthesis; thereby increasing parathyroid hormone (PTH) production. FGF-23 acts on the parathyroid gland (PTG) to increase 1α-hydroxylase activity and results in increase intra-gland 1,25D production that attenuates PTH secretion efficiently if sufficient 25D are available. Interesting, calcimimetics can further increase PTG 1α-hydroxylase activity that emphasizes the demand for nutritional vitamin D (NVD) under high PTH status. Read More

View Article
December 2018
1 Read

Phosphate binder choices used in ESRD patients.

Nephrol News Issues 2016 Aug;30(8):37-38

Chronic kidney disease is a complex disease, and one of its common complications is associated with hyperphosphatemia. This can lead to the development of severe hyperparathyroidism, soft tissue calcification, calcification of the lung, morbidity, and mortality. One of the mainstream therapies for managing hyperphosphatemia are phosphate binder medications (PBMs). Read More

View Article

Systematic review of cure and recurrence rates following minimally invasive parathyroidectomy.

BJS Open 2018 Dec 28;2(6):364-370. Epub 2018 May 28.

Department of Ear, Nose and Throat, Head and Neck Surgery St George's Hospital London UK.

Background: The majority of patients with primary hyperparathyroidism (PHPT) have a single overactive adenoma. Advances in preoperative imaging and surgical adjuncts have given rise to minimally invasive parathyroidectomy (MIP), with lower complication rates in comparison with bilateral neck exploration. Misdiagnosis and undertreatment of multiglandular disease, leading to potentially higher recurrence rates, remains a concern. Read More

View Article
December 2018
1 Read

Correction: Normocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary Referral Population.

Horm Metab Res 2018 Nov 29;50(11):e7. Epub 2018 Nov 29.

Department of Oncologic Surgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Belgium.

View Article
November 2018

Renal failure and progressive pancytopenia.

Authors:
J H Yeo A Islam

J R Coll Physicians Edinb 2018 Dec;48(4):318-320

Southend Hospital, Southend-on-Sea, UK.

Hyperparathyroidism may be a precipitating factor to the development of myelofibrosis; however, this is extremely rare with only a few documented case reports of myelofibrosis caused by secondary hyperparathyroidism. We describe a case of a 24-year-old female who had a failed live donor renal transplant and secondary hyperparathyroidism. While on haemodialysis she became increasingly pancytopenic despite erythropoietin injections and adequate iron, vitamin B12 and folate replacement. Read More

View Article
December 2018
1 Read

[Secondary osteoporosis. Surgical treatment for patients with secondary osteoporosis.]

Clin Calcium 2018 ;28(12):1671-1677

Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

In the etiology of secondary osteoporosis, only primary hyperparathyroidism is the one to which osteoporosis itself is indicated for surgery. However, there are several diseases that may give bone a good environment by surgical treatment for primary diseases such as hyperthyroidism or Cushing's syndrome, and secondary osteoporosis may improve. It is important to properly conduct differential diagnosis and to discuss and determine surgical indication. Read More

View Article
January 2018
1 Read

[Secondary osteoporosis. Secondary osteoporosis by primary hyperparathyroidism.]

Authors:
Yasuo Imanishi

Clin Calcium 2018 ;28(12):1627-1634

Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.

Primary hyperparathyroidism(PHPT)is one of the common endocrine disorders, which results clinically in secondary osteoporosis. PHPT also occurs nephrolithiasis, muscle weakness, cardiac and psychiatric abnormalities even in a mild or asymptomatic disease. Parathyroidectomy(PTX)is the only definitive treatment for PHPT. Read More

View Article
January 2018
4 Reads

[Secondary osteoporosis. Disordered bone metabolism in chronic kidney disease.]

Clin Calcium 2018 ;28(12):1611-1618

Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine/The Institute of Medical Sciences, Tokai University, Isehara, Japan.

In patients with chronic kidney disease(CKD), mineral metabolism abnormalities such as hyperphosphatemia, decreased 1,25-dihydroxyvitamin D, and elevated parathyroid hormone develop as kidney function declines, which lead to vascular calcification and a variety of skeletal abnormalities, collectively termed renal osteodystrophy. Because CKD patients have increased risk of bone fractures, it is important to assess fracture risk by measuring bone mineral density and bone metabolism markers. In addition to management of secondary hyperparathyroidism, medications for osteoporosis could be a reasonable option for preventing fracture. Read More

View Article
January 2018

Parathyroidectomy decreases serum intact parathyroid hormone and calcium levels and prolongs overall survival in elderly hemodialysis patients with severe secondary hyperparathyroidism.

J Clin Lab Anal 2018 Nov 28:e22696. Epub 2018 Nov 28.

Department of Thyroid Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: The objective of this study was to assess the effect of parathyroidectomy (PTX) treatment on prolonging overall survival (OS) as well as decreasing levels of intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus (P) in elderly hemodialysis patients with severe secondary hyperparathyroidism (SHPT).

Methods: A total of 304 elderly hemodialysis patients with severe SHPT were consecutively enrolled in this cohort study. According to whether PTX operations were applied, patients were classified into PTX group (N = 112) and Control group (N = 192) and were followed up for 3 years. Read More

View Article
November 2018

Parathyroid imaging by (18)F-fluorocholine PET/CT in patients with primary hyperparathyroidism and inconclusive conventional methods: clinico-pathological correlations.

Physiol Res 2018 Nov;67(Supplementum 3):S551-S557

Institute of Endocrinology, Prague, Czech Republic.

(18)F-fluorocholine positron emission tomography/computed tomography (FCH) was performed after inconclusive neck ultrasound and (99)Tc-sestaMIBI SPECT (MIBI) scintigraphy in patients with primary hyperparathyroidism (PHPT) to localize abnormal parathyroid glands before surgery. The results were retrospectively evaluated and compared to postoperative histopathological findings. 13 patients with PHPT were enrolled (mean age 64. Read More

View Article
November 2018
1 Read

Evaluation of renal osteodystrophy in the dental clinic by assessment of mandibular and phalangeal cortical indices.

Oral Radiol 2018 May 4;34(2):172-178. Epub 2017 Sep 4.

Faculdade de Odontologia, Campus de São José dos Campos, Universidade Estadual Paulista Julio de Mesquita Filho, Avenida Engenheiro Francisco José Longo, No. 777-Bairro: Jardim São Dimas, São Paulo, 12245-000, Brazil.

Objectives: Secondary hyperparathyroidism (SHPT) is a disease that affects patients with chronic kidney disease, and is characterized by mineral disturbance and bone loss, known as renal osteodystrophy. The aim of this study was to assess the validity of using intraoral phosphor storage plates to take radiographs of the middle phalanges to evaluate bone loss resulting from SHPT during follow-up of these patients.

Methods: The sample consisted of 24 patients with chronic kidney disease, 12 with parathyroid hormone (PTH) levels ≥500 pg/ml, and 12 with PTH levels <500 pg/ml, who underwent hemodialysis weekly. Read More

View Article
May 2018
1 Read

Analysis of the Increase in Bone Mineral Density After Surgical Treatment of Primary Hyperparathyroidism.

J Clin Densitom 2018 Nov 9. Epub 2018 Nov 9.

MD, General and Digestive Surgeon, Department of General and Digestive Surgery, Endocrine Surgery Unit, Príncipe de Asturias Teaching Hospital, Alcalá de Henares, Madrid, Spain.

Aim: To analyze the effect of the surgery in bone mineral density (BMD) and to study the value of preoperative clinical and analytical factors as predictors of bone increase.

Material And Methods: Prospective observational study. Postmenopausal women who were operated for primary hyperparathyroidism were included. Read More

View Article
November 2018
1 Read
1.603 Impact Factor

Electrolytes disturbances after kidney transplantation.

Acta Clin Belg 2018 Nov 27:1-5. Epub 2018 Nov 27.

c Antwerp University Hospital and University of Antwerp , Edegem.

Objectives: Water and electrolytes disturbances often occur in renal transplant recipients. The objective is to describe the pathophysiology and the treatment of the most prevalent abnormalities.

Methods: We screened PubMed for the following words in various combination: kidney transplantation and (disturbances or abnormalities) of (electrolytes or sodium or potassium or phosphate or calcium or acid-base). Read More

View Article
November 2018
1 Read

Bone health among patients with primary aldosteronism: a systematic review and meta-analysis.

Minerva Endocrinol 2018 Nov 26. Epub 2018 Nov 26.

Clinical Academic Unit, Newcastle University Medicine Malaysia, Johor, Malaysia.

Background: Recent studies showed a possible association between hyperaldosteronism and secondary hyperparathyroidism leading to reduced bone health, however results are conflicting.

Methods: We conducted a meta-analysis to evaluate the relationship between primary aldosteronism (PA) with bone biochemical markers and to assess bone mineral density in patients with primary aldosteronism.

Results: A total of 939 subjects were examined (37. Read More

View Article
November 2018

Primary hyperparathyroidism: Labs to order, Tx to consider.

J Fam Pract 2018 Nov;67(11):E16-E21

University of Mississippi Medical Center, Jackson, Mississippi, USA.

Unexplained kidney stones, osteoporosis, or certain subtle clues may point to hyperparathyroidism. These tests and imaging options can help you to be sure. Read More

View Article
November 2018
1 Read

An Unusual Mass of Posterior Mediastinum: A Case of Retrotracheal Parathyroid Adenoma Presenting With Primary Hyperparathyroidism.

Clin Med Insights Circ Respir Pulm Med 2018 16;12:1179548418811840. Epub 2018 Nov 16.

Department of Thoracic Surgery, CHU Hassan II, Fès, Morocco.

Although parathyroid ectopy in the mediastinum has been the subject of several publications, its location in the posterior mediastinum is very rarely reported. We report a case of a 69-year-old patient who presented with clinical symptoms of malignant hypercalcemia due to a retrotracheal mediastinal parathyroid adenoma. The surgical excision leads to a quick normalisation of the phosphocalcic balance with improvement of the clinical symptoms. Read More

View Article
November 2018
3 Reads

Evaluating a shortened interpretation criterion for intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism: A 5-minutes criterion in primary hyperparathyroidism and intraoperative algorithm.

Head Neck 2018 Nov 26. Epub 2018 Nov 26.

Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.

Background: Most criteria require a parathyroid hormone (PTH) decline of ≥50% within 10 minutes after excision of the gland during surgery for primary hyperparathyroidism. The aim was to evaluate a model allowing earlier prediction of cure.

Methods: One thousand eighteen patients with primary hyperparathyroidism were included. Read More

View Article
November 2018
2 Reads

Primary hyperparathyroidism.

Best Pract Res Clin Endocrinol Metab 2018 Sep 28. Epub 2018 Sep 28.

Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address:

Primary hyperparathyroidism (PHPT), the most common cause of hypercalcemia, is most often identified in postmenopausal women with hypercalcemia and parathyroid hormone (PTH) levels that are either frankly elevated or inappropriately normal. The clinical presentation of PHPT includes three phenotypes: target organ involvement of the renal and skeletal systems; mild asymptomatic hypercalcemia; and more recently, high PTH levels in the context of persistently normal albumin-corrected and ionized serum calcium values. The factors that determine which of these three clinical presentations is more likely to predominate in a given country include the extent to which biochemical screening is employed, the prevalence of vitamin D deficiency, and whether a medical center or practitioner tends to routinely measure PTH levels in the evaluation of low bone density or frank osteoporosis. Read More

View Article
September 2018
1 Read

Molecular pathogenesis of parathyroid tumours.

Best Pract Res Clin Endocrinol Metab 2018 Nov 20. Epub 2018 Nov 20.

Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, Division of Medical Genetics, Italy. Electronic address:

Parathyroid tumors represent an elusive endocrine neoplasia, which lead to primary hyperparathyroidism, pHPT, a common endocrine calcium disorder characterized by hypercalcemia and normal-high parathormone secretion. Parathyroid tumours are benign adenomas or multiple glands hyperplasia in the vast majority (>99% of cases), while malignant neoplasms are rare (less than 1%). Despite pHPT is a common disorder, our knowledge about the genetic predisposition and molecular pathophysiology is limited to the familial syndromic forms of parathyroid tumour, that, however, represent not more than the 10% of all the cases; instead, the pathophysiology of sporadic forms remains an open field, although data about epigenetic mechanisms or private genes have been supposed. Read More

View Article
November 2018
1 Read

Molecular genetic insights into sporadic primary hyperparathyroidism.

Endocr Relat Cancer 2019 Feb;26(2):R53-R72

Center for Molecular Oncology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by dysregulation of parathyroid hormone release. The large majority of PHPT cases are attributable to sporadic, single-gland parathyroid adenoma, in which MEN1 and CCND1/cyclin D1 are the most well-established drivers of tumorigenesis. Sporadic parathyroid carcinoma, which appears to mostly arise through molecular pathways distinct from those causing benign parathyroid tumors, is rare and is most frequently driven by mutational inactivation of the CDC73 (HRPT2) tumor suppressor gene. Read More

View Article
February 2019
1 Read

Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-Label Study.

Clin Ther 2018 Nov 22. Epub 2018 Nov 22.

Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Purpose: Secondary hyperparathyroidism (SHPT) is a serious complication that increases the risk of bone disorders in patients with chronic kidney disease (CKD) undergoing hemodialysis. Etelcalcetide is the first injectable calcimimetic approved for treatment of SHPT, which reduces bone turnover markers and suppresses intact fibroblast growth factor 23 (iFGF-23). This study aimed to explore the associations between etelcalcetide-induced changes in circulating factors and serum iFGF-23 levels. Read More

View Article
November 2018
1 Read

Analysis of the role of thyroidectomy and thymectomy in the surgical treatment of secondary hyperparathyroidism.

Am J Otolaryngol 2019 Jan - Feb;40(1):67-69. Epub 2018 Oct 22.

Division of Head and Neck Surgery, Department of Ophthalmology, Otolaryngology, Head and Neck Surgery, Ribeirao Preto Medical School, University of Sao Paulo, Brazil. Electronic address:

Purpose: Parathyroidectomy can be subtotal or total with an autograft for the treatment of renal hyperparathyroidism. In both cases, it may be extended with bilateral thymectomy and total or partial thyroidectomy. Thymectomy may be recommended in combination with parathyroidectomy in order to prevent mediastinal recurrence. Read More

View Article
October 2018
2 Reads

Intraoperative Probe-Based Confocal Endomicroscopy to Histologically Differentiate Thyroid From Parathyroid Tissue Before Resection.

Surg Innov 2018 Nov 23:1553350618814078. Epub 2018 Nov 23.

1 University Hospital of Strasbourg, Strasbourg, France.

Background: Frozen section is the standard method to histologically distinguish parathyroid tissue from thyroid tissue during endocrine neck surgery. Frozen section can be time-consuming and costly. Its drawback is that it is to be performed only after the removal of a suspected pathological tissue. Read More

View Article
November 2018
6 Reads

Growing Human Parathyroids in a Microphysiological System: A Novel Approach to Understanding and Developing New Treatments for Hyperparathyroidism.

Cells Tissues Organs 2018 Nov 22:1-8. Epub 2018 Nov 22.

Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.

We developed a novel model for studying hyperparathyroidism by growing ex vivo 3-dimensional human parathyroids as part of a microphysiological system (MPS) that mimics human physiology. The purpose of this study was to validate the parathyroid portion of the MPS. We prospectively collected parathyroid tissue from 46 patients with hyperparathyroidism for growth into pseudoglands. Read More

View Article
November 2018
1 Read

Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.

J Nephrol 2018 Nov 21. Epub 2018 Nov 21.

Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Aims: Cardiovascular (CV) complications are common in chronic kidney disease (CKD). Numerous metabolic disturbances including hyperphosphatemia, high circulating calciprotein particles (CPP), hyperparathyroidism, metabolic acidosis, and magnesium deficiency are associated with, and likely pathogenic for CV complications in CKD. The goal of this feasibility study was to determine whether effervescent calcium magnesium citrate (EffCaMgCit) ameliorates the aforementioned pathogenic intermediates. Read More

View Article
November 2018
4 Reads

A comprehensive overview on osteoporosis and its risk factors.

Ther Clin Risk Manag 2018 6;14:2029-2049. Epub 2018 Nov 6.

Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang, Malaysia.

Osteoporosis is a bone disorder with remarkable changes in bone biologic material and consequent bone structural distraction, affecting millions of people around the world from different ethnic groups. Bone fragility is the worse outcome of the disease, which needs long term therapy and medical management, especially in the elderly. Many involved genes including environmental factors have been introduced as the disease risk factors so far, of which genes should be considered as effective early diagnosis biomarkers, especially for the individuals from high-risk families. Read More

View Article
November 2018

Timely Evaluation and Management of Primary Hyperparathyroidism in Patients With Kidney Stones.

J Surg Res 2018 Dec 7;232:564-569. Epub 2018 Aug 7.

Division of Endocrine Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address:

Background: Nephrolithiasis is a classic, treatable manifestation of primary hyperparathyroidism (PHPT). We examined predictors of kidney stone formation in PHPT patients and determined how efficiently the diagnosis of PHPT is made in patients whose initial presentation is with stones.

Materials And Methods: We performed a retrospective analysis of surgically treated PHPT patients, comparing 247 patients who were kidney stone formers and 1047 patients with no kidney stones. Read More

View Article
December 2018
3 Reads

Calcium phosphate product level as a predictor for arteriovenous fistula re-operations in patients with chronic renal failure.

Vascular 2018 Nov 21:1708538118814611. Epub 2018 Nov 21.

2 Department of Pediatric Cardiovascular Surgery, Mersin City Education and Research Hospital, Turkey.

Objectives: There is an increased calcium phosphate product level causing the formation of calcification in the arterial wall and thus decreased quality of fistula in patients with chronic renal failure. The purpose of our study is to verify the relationship between arteriovenous fistula re-operation and high calcium phosphate product level.

Methods: Seventy-nine consecutive patients with chronic renal failure between April 2016 and February 2018 were included in the study. Read More

View Article
November 2018
5 Reads

The diagnostic value of parathyroid hormone washout in primary hyperparathyroidism patients with negative or equivocal 99 m Tc-MIBI results.

Diagn Cytopathol 2018 Nov 21. Epub 2018 Nov 21.

Department of Endocrinology and Metabolism, Faculty of Medicine, Ataturk Education and Research Hospital, Yildirim Beyazit University, Ankara, Turkey.

Background And Objectives: The accurate identification of hyper functioning parathyroid gland is needed for definitive surgical treatment in primary hyperparathyroidism. Ultrasonography and 99mTechnetium sestamibi scintigraphy are the two most used methods with varying sensitivities. This study aimed to assess the value of parathyroid hormone (PTH) assay in preoperative ultrasound guided fine needle aspiration (FNA)-PTH washout fluid to verify the correct localisation of lesions with negative or inconclusive scintigraphy results. Read More

View Article
November 2018
2 Reads

Intraoperative Decision-Making and Technical Aspects of Parathyroidectomy in Young Patients With MEN1 Related Hyperparathyroidism.

Front Endocrinol (Lausanne) 2018 16;9:618. Epub 2018 Oct 16.

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

One in 5,000 to 1 in 50,000 births have multiple endocrine neoplasia type 1 (MEN1). MEN1 is a hereditary syndrome clinically defined by the presence of two of the following endocrine tumors in the same patient: parathyroid adenomas, entero-pancreatic endocrine tumors and pituitary tumors. Most commonly, patients with MEN1 manifest primarily with signs and symptoms linked to primary hyperparathyroidism. Read More

View Article
October 2018
1 Read

Does renal function improve after parathyroidectomy in primary hyperparathyroidism?

Nefrologia 2018 Nov 17. Epub 2018 Nov 17.

Servicio de Nefrología, Hospital Universitario Doce de Octubre, Madrid, España; Departamento de Medicina, Universidad Complutense, Madrid, España.

Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterised by hypercalcaemia and parathormone increase. Decreased glomerular filtration rate (<60ml/min) continues to be a parathyroidectomy (PTX) criterion in asymptomatic PHPT. The influence of PTX on renal function evolution is the subject of debate. Read More

View Article
November 2018
6 Reads

Sestamibi Scanning and Intraoperative Parathyroid Hormone Results for Parathyroid Resection in Primary Hyperparathyroidism.

Am Surg 2018 Aug;84(8):e325-e327

Division of Acute Care Surgery and Trauma, Memorial Regional Hospital, Hollywood, Florida, USA.

View Article
August 2018
1 Read

CDC73 germline mutation in a family with mixed epithelial and stromal tumors.

Urology 2018 Nov 16. Epub 2018 Nov 16.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892. Electronic address:

Objective: To describe a family in which three members presented with mixed epithelial tumor of the kidney (MEST) and were found to possess a germline mutation in CDC73, a gene which is associated with hyperparathyroidism-jaw tumor syndrome (HPT-JT).

Materials And Methods: Blood and tumor DNA from three family members who presented with a primary diagnosis of MEST was subjected to targeted gene sequencing to identify potential genetic components.

Results: A germline start codon mutation (p. Read More

View Article
November 2018
6 Reads

Redox State of Human Serum Albumin and Inflammatory Biomarkers in Hemodialysis Patients with Secondary Hyperparathyroidism During Oral Calcitriol Supplementation for Vitamin D.

Open Med Chem J 2018 18;12:98-110. Epub 2018 Oct 18.

Consultant Nephrologist, Nephrology Unit, Al-Rahma Hospital, Madinah, Saudi Arabia.

Background: Hemodialysis (HD) patients with secondary Hyperparathyroidism (s-HPT) are exposed to increased inflammation and oxidative stress. In HD patients, oxidized albumin is a reliable marker of oxidative stress and its clinical significance has been rarely studied.

Objective: The objective of this study was to evaluate Cys34 Human Serum Albumin (HSA) as oxidative stress biomarker in HD patients with s-HPT and its relationship with inflammation on bone turnover markers during oral calcitriol supplementation for vitamin D. Read More

View Article
October 2018
3 Reads

Familial hypocalciuric hypercalcemia and related disorders.

Best Pract Res Clin Endocrinol Metab 2018 Oct 26;32(5):609-619. Epub 2018 May 26.

Endocrine Research Unit, San Francisco Veterans Affairs Health Care System, Department of Medicine, University of California, San Francisco, United States. Electronic address:

Familial hypocalciuric hypercalcemia (FHH) causes hypercalcemia by three genetic mechanisms: inactivating mutations in the calcium-sensing receptor, the G-protein subunit α, or adaptor-related protein complex 2, sigma 1 subunit. While hypercalcemia in other conditions causes significant morbidity and mortality, FHH generally follows a benign course. Failure to diagnose FHH can result in unwarranted treatment or surgery for the mistaken diagnosis of primary hyperparathyroidism (PHPT), given the significant overlap of biochemical features. Read More

View Article
October 2018
1 Read

Primary hyperparathyroidism.

Best Pract Res Clin Endocrinol Metab 2018 Oct 22;32(5):593-607. Epub 2018 Sep 22.

Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address:

Primary hyperparathyroidism (PHPT), the most common cause of hypercalcemia, is most often identified in postmenopausal women with hypercalcemia and parathyroid hormone (PTH) levels that are either frankly elevated or inappropriately normal. The clinical presentation of PHPT includes three phenotypes: target organ involvement of the renal and skeletal systems; mild asymptomatic hypercalcemia; and more recently, high PTH levels in the context of persistently normal albumin-corrected and ionized serum calcium values. The factors that determine which of these three clinical presentations is more likely to predominate in a given country include the extent to which biochemical screening is employed, the prevalence of vitamin D deficiency, and whether a medical center or practitioner tends to routinely measure PTH levels in the evaluation of low bone density or frank osteoporosis. Read More

View Article
October 2018
6 Reads

Choline PET/CT in parathyroid imaging: a systematic review.

Nucl Med Commun 2018 Nov 15. Epub 2018 Nov 15.

Department of Nuclear Medicine, Northwest Clinics, Alkmaar, The Netherlands.

One of the most promising imaging techniques in primary hyperparathyroidism is PET/CT with choline-based tracers. To investigate the current evidence of these tracers in localizing parathyroid adenoma, a systematic review was performed. A comprehensive literature search was carried out and eligible studies were analyzed. Read More

View Article
November 2018
2 Reads

MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in Pregnancy: Review and Evidence Based Recommendations for Management.

Eur J Endocrinol 2018 Nov 1. Epub 2018 Nov 1.

M Brandi, Department of Surgery and Translational Medicine, University of Florence, Florence, 50139, Italy.

Purpose: review calcium homeostasis in pregnancy and provide evidence based best practice recommendations for the management of hypoparathyroidism in pregnancy Methods: We searched MEDLINE, EMBASE and Cochrane databases from January 2000 to April 1, 2018. A total of 65 articles were included in the final review.

Conclusions: During pregnancy calcitriol levels increase by 2-3 fold resulting in enhanced intestinal calcium absorption. Read More

View Article
November 2018
4 Reads

The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases.

Nat Rev Endocrinol 2018 Nov 15. Epub 2018 Nov 15.

Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

The Ca-sensing receptor (CaSR) is a dimeric family C G protein-coupled receptor that is expressed in calcitropic tissues such as the parathyroid glands and the kidneys and signals via G proteins and β-arrestin. The CaSR has a pivotal role in bone and mineral metabolism, as it regulates parathyroid hormone secretion, urinary Ca excretion, skeletal development and lactation. The importance of the CaSR for these calcitropic processes is highlighted by loss-of-function and gain-of-function CaSR mutations that cause familial hypocalciuric hypercalcaemia and autosomal dominant hypocalcaemia, respectively, and also by the fact that alterations in parathyroid CaSR expression contribute to the pathogenesis of primary and secondary hyperparathyroidism. Read More

View Article
November 2018
5 Reads

Hypoparathyroidism in children: a study of eight cases.

Tunis Med 2018 Aug - Sep;96(8-09):472-476

Background: Hypoparathyroidism is a rare pediatric endocrine disease, which is caused by low circulating levels of PTH or insensitivity to its action in the target tissues.

Aim: To report the clinical and biochemical characteristics and theoutcome of 8 patients with hypoparathyroidism.

Methods: We analyzed retrospectively the results of clinical, biochemical, radiological findings of patients with hypoparathyroidism diagnosed in pediatric department of Hedi Chaker Hospital during the period 1994-2013. Read More

View Article
November 2018
8 Reads

Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients.

Orphanet J Rare Dis 2018 Nov 14;13(1):205. Epub 2018 Nov 14.

Department of Surgery and Translational Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy.

Background: Multiple endocrine neoplasia (MEN1) is a rare inherited multi-tumour syndrome, affecting specific neuroendocrine organs and non-endocrine tissues with a variable spectrum of over 20 possible different combinations, caused by inactivating heterozygote mutations of the MEN1 gene. Disease onset, penetrance, clinical presentation, course and prognosis are all extremely variable, even among individuals bearing the same causative mutation, which doesn't allow prediction of the individual clinical phenotype (based on the specific result of the genetic test), thus compelling all patients and mutation carriers to undergo a common routine general screening program.

Results: We performed an extensive epidemiological, clinical and genetic analysis of the Florentine MEN1 patient database, which includes 145 MEN1 patients and 20 asymptomatic MEN1 carriers, constantly followed up at the Regional Referral Centre for Inherited Endocrine Tumours of the Tuscany Region, during the last three decades. Read More

View Article
November 2018
3 Reads

Autoinfarction of Giant Parathyroid Adenoma after Preoperative Withdrawal of Anticoagulants.

Case Rep Surg 2018 23;2018:9261749. Epub 2018 Oct 23.

Division of General Surgery, Department of Surgery, University Health Network, Canada.

A 71-year-old man with known history of atrial fibrillation (treated with routine rivaroxaban therapy) was found to have incidental biochemical elevated calcium and parathyroid hormone (PTH) levels. His physical examination demonstrated the presence of a palpable right neck mass. Subsequent imaging studies revealed a large parathyroid mass as well as multiple bone lesions, raising the suspicion of parathyroid carcinoma. Read More

View Article
October 2018
5 Reads